Demographics, Prognostic Factors, and Treatment Outcomes of Adrenocorticotrophic Carcinoma: A SEER Database Analysis From 1988-2008

248 Background: The objective of this study was to assess relationships between race, treatment, and cause-specific mortality for prostate cancer. Methods: The Surveillance, Epidemiology and End Results (SEER) database yielded 328,151 prostate cancer patients diagnosed between 1990–2007 including 5,129 Japanese-American, 50,717 Black-American, and 282,305 White-American men. Japanese-American men were selected as they have the lowest incidence of prostate cancer and best treatment outcomes. Cox proportional-hazards regression analysis was used to assess association of race with prostate-cancer specific mortality before and after adjusting for age, health, and treatment. To assess impact of race on treatment selection, we compared mean incidence of treatment type [external beam radiation therapy (EBRT), brachytherapy, and surgery] by race using one-way ANOVA and post-testing with Bonferroni correction. Results: Race significantly impacted survival after prostate cancer treatment. Blacks had the highest (HR= 1.198; 95% CI: 1.159 to 1.239, p< .001) and Japanese the lowest (HR= .618; 95% CI: .560 to .682, p< .001) mortality hazard compared to Whites. Tumor grade was the strongest predictor of survival (p< .001). Treatment was also significant: Brachytherapy had the lowest mortality hazard for radiation treatments and surgery was associated with lower mortality hazard compared to no surgery. 37.8%, 44.1%, and 29.1% of Blacks, Whites, and Japanese-Americans underwent surgery (p< .05), 27.3%, 23.8%, and 38.2% of Blacks, Whites, and Japanese-Americans underwent EBRT, (p< .05), and 4.9%, 6.7%, and 4.7% of Blacks, Whites, and Japanese-Americans underwent brachytherapy, with Whites significantly different from the other groups( p<.05). Conclusions: SEER database analysis revealed race impacts prostate cancer survival. Treatment selection for prostate cancer differs among racial groups and race is associated with differential treatment outcomes. Comparisons between treatments must be viewed with caution as confounding variables likely exist not accounted for in the SEER database. Future research on race, treatment, and socioeconomic impact on cancer-specific mortality is warranted.

Download Full-text

Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database

Open Medicine ◽

10.1515/med-2021-0215 ◽

2021 ◽

Vol 16 (1) ◽

pp. 169-174

Author(s):

Lei Lei ◽

Liu Yang ◽

Yang-yang Xu ◽

Hua-fei Chen ◽

Ping Zhan ◽

...

Keyword(s):

Prognostic Factors ◽

Clinical Features ◽

Survival Benefit ◽

Stage Iv ◽

Primary Lesion ◽

Hepatoid Adenocarcinoma ◽

Seer Database ◽

Primary Tumor Size ◽

Adenocarcinoma Of The Lung ◽

To Receive

Abstract Hepatoid adenocarcinoma of the lung (HAL) is a rare malignant tumor that is defined as a primary alpha-fetoprotein (AFP)-producing lung carcinoma. We aimed to identify prognostic factors associated with the survival of patients with HAL using data from the Surveillance, Epidemiology, and End Results (SEER) database. We collected data from patients diagnosed with HAL, adenocarcinoma (ADC), and squamous cell carcinoma (SCC) of the lung between 1975 and 2016 from the SEER database. The clinical features of patients with ADC and SCC of the lung were also analyzed. The clinical features of HALs were compared to ADCs and SCCs. A chi-square test was used to calculate the correlations between categorical variables, and a t test or Mann–Whitney U test was used for continuous variables. The Kaplan–Meier method and Cox regression analysis were used to identify the prognostic factors for the overall survival (OS) of HALs. Two-tailed p values < 0.05 were considered statistically significant. Sixty-five patients with HAL, 2,84,379 patients with ADC, and 1,86,494 with SCC were identified from the SEER database. Fewer males, advanced stages, and more chemotherapy-treated HALs were found. Compared to patients with SCC, patients with HAL were less likely to be male, more likely to be in an advanced stage, and more likely to receive chemotherapy (p < 0.05). The American Joint Committee on Cancer staging was the only prognostic factor for OS in patients with HAL, and stage IV was significantly different from other stages (hazard ratio = 0.045, 95% confidence interval: 0.005–0.398, p = 0.005). Males with HAL were more likely to receive radiotherapy compared to females with HAL (61.8 vs 31.5%, p = 0.034). Younger patients with HAL were more likely to receive chemotherapy (59.4 + 10.2 years vs 69 + 11.3 years, p = 0.001). The primary tumor size of HAL was associated with the location of the primary lesion (p = 0.012). No conventional antitumor therapies, including surgery, chemotherapy, and radiotherapy, were shown to have a significant survival benefit in patients with HAL (p > 0.05). This study showed that stage IV was the only prognostic factor for OS in HALs compared to other clinicopathologic factors. Conventional antitumor therapies failed to show survival benefit; thus, a more effective method by which to treat HAL is needed. Interestingly, the clinical features and the location of the primary lesion were shown to be associated with primary tumor size and treatment in patients with HAL, which have not been reported before.

Download Full-text

Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer

Acta Oncologica ◽

10.1080/0284186x.2021.1918763 ◽

2021 ◽

pp. 1-10

Author(s):

Kathinka S. Slørdahl ◽

Dagmar Klotz ◽

Jan-Åge Olsen ◽

Eva Skovlund ◽

Christine Undseth ◽

...

Keyword(s):

Prognostic Factors ◽

Treatment Outcomes ◽

Anal Cancer

Download Full-text

Prognostic significance of bladder neck involvement in non‐muscle‐invasive bladder cancer: A SEER database analysis with 19,919 patients

Cancer Medicine ◽

10.1002/cam4.4219 ◽

2021 ◽

Author(s):

Xiangpeng Zhan ◽

Ju Guo ◽

Luyao Chen ◽

Wen Deng ◽

Xiaoqiang Liu ◽

...

Keyword(s):

Bladder Cancer ◽

Bladder Neck ◽

Prognostic Significance ◽

Invasive Bladder Cancer ◽

Seer Database ◽

Database Analysis ◽

Muscle Invasive Bladder Cancer ◽

Muscle Invasive

Download Full-text

Clinicopathological Features, Prognostic Factors, Survival Trends, and Treatment of Malignant Ovarian Germ Cell Tumors: A SEER Database Analysis

Oncology Research and Treatment ◽

10.1159/000509189 ◽

2021 ◽

Vol 44 (4) ◽

pp. 145-152

Author(s):

Hualei Guo ◽

Hao Chen ◽

Wenhui Wang ◽

Lingna Chen

Keyword(s):

Prognostic Factors ◽

Germ Cell ◽

Proportional Hazards ◽

Germ Cell Tumors ◽

Cox Proportional Hazards ◽

Low Grade ◽

Seer Database ◽

Survival Times ◽

Survival Curves ◽

Significant Difference

Objective: The aim of this study was to investigate the clinicopathological prognostic factors of malignant ovarian germ cell tumors (MOGCT) and evaluate the survival trends of MOGCT by histotype. Methods: We extracted data on 1,963 MOGCT cases diagnosed between 2000 and 2014 from the Surveillance, Epidemiology, and End Results (SEER) database and the histological classification of MOGCT, including 5 categories: dysgerminoma, embryonal carcinoma (EC), yolk sac tumor, malignant teratoma, and mixed germ cell tumor. We examined overall and disease-specific survival of the 5 histological types. Kaplan-Meier and Cox proportional hazards regression models were used to estimate survival curves and prognostic factors. We also estimated survival curves of MOGCT according to different treatments. Results: There was a significant difference in prognosis among different histological classifications. Age, histotype, grade, SEER stage, and surgery were independent prognostic factors for survival of patients with MOGCT. For all histotypes, 1-, 3-, and 5-year survival rate estimates were >85%, except for EC, which had the worst outcomes at 1 year (55.6%), 3 years (44.4%), and 5 years (33.3%). In the distant SEER stage, both chemotherapy and surgery were associated with improved survival outcomes compared with surgery- and chemotherapy-only groups. Conclusions: Dysgerminoma patients had the most favorable outcomes, whereas EC patients had the worst survival. A young age, low grade, and surgery were all significant predictors for improved survival. In contrast, a distant SEER stage was a risk factor for poor survival. Chemotherapy combined with surgery contributed to longer survival times of patients with MOGCT in the distant SEER stage.

Download Full-text